Invitae

Invitae is a genetic information company focused on improving healthcare through the integration of genetic information into routine medical practice. It specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates numerous genetic tests into a single platform. This approach aims to provide higher quality results with faster turnaround times and lower costs compared to traditional single-gene tests. Invitae's offerings encompass a wide range of genetic tests related to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric disorders, and metabolic disorders. By making genetic testing more affordable and accessible, establishing a secure infrastructure for genome management, and fostering a collaborative community for sharing genetic information, Invitae seeks to advance both science and medicine, ultimately enhancing healthcare for a global population.

7 past transactions

ArcherDX

Acquisition in 2020
ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays.

YouScript

Acquisition in 2020
YouScript is a provider of precision medication management services.

Diploid

Acquisition in 2020
Diploid is a provider of biotechnology services.

Genelex

Acquisition in 2020
Genelex is a leader in precision medication management. A pioneer in DNA testing since 1987, Genelex now focuses exclusively on pharmacogenetic testing. Backed by a powerful combination of innovative analytics software, state-of art laboratory facilities, and expert staff, Genelex has a longstanding commitment to the prevention of dangerous and life-threatening adverse drug events (ADEs).

Clear Genetics

Acquisition in 2019
Clear Genetics is a digital health company dedicated to the thoughtful integration of genetics into routine patient care. Clear Genetics partners with health systems, labs and academic institutions to increase patient access to genetic counseling and testing.

Jungla

Acquisition in 2019
Headquartered in South San Francisco, Jungla is a biotechnology company delivering robust and scalable results for clinical genetic and genomic testing. To achieve this, Jungla develops and combines advances in functional genomics, computational biophysics, and computer science to proactively inform on the risk of variants in our genome. Jungla aims to empower clinical genetic testing with quantitative, model-driven guidance to complement and enhance observational data. Whereas existing solutions routinely used in the market have demonstrably poor accuracies, Jungla delivers robust, scalable, and auditable support with dramatically higher accuracies and increasingly mechanistic cellular and biophysical insights. We are supported by leading technology and healthcare investors.

CancerGene Connect

Acquisition in 2017
CancerGene Connect represents the power of evolving technology in healthcare science. With each generation of improvement, our platform makes significant strides in pedigree generation and risk modeling–bringing increasingly powerful connections to thousands of patients and practices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.